Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 01 2021 - 8:20AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month March 2021
(Commission File No. 001-35193)
Grifols, S.A.
(Translation of registrant’s name
into English)
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles 08174
Barcelona, Spain
(Address of registrant’s principal
executive office)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x
Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes ¨
No x
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes ¨ No x
Indicate by check mark whether the registrant by furnishing
the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
Yes ¨
No x
If “Yes” is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82- . .
Grifols, S.A.
TABLE OF CONTENTS
|
Grifols, S.A.
|
|
Avinguda de la Generalitat 152-158
08174 Sant Cugat del Vallès
Barcelona - ESPAÑA
|
|
Tel. [34] 935 710 500
|
Fax [34] 935 710 267
|
|
www.grifols.com
|
Pursuant to the provisions of article 227
of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols,
S.A. ("Grifols") hereby informs about the following
OTHER RELEVANT INFORMATION
Grifols informs that it has closed
the transaction to acquire 25 U.S. based plasma donation centers from BPL Plasma, Inc, a subsidiary of Bio Products
Laboratory Holdings Limited, for a total purchase price of USD 370 million. The 25 centers acquired are authorized by the
U.S. Food and Drug Administration (FDA) and the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) and
during last year collected approximately one million liters of plasma. Grifols will have immediate access to the plasma
obtained from these centers.
The transaction has received the applicable regulatory clearances,
and will be financed from Grifols’ own resources.
In 2021, Grifols is ready for a rebound
in its plasma-collection levels in the wake of wider vaccination deployments and the ease of COVID-19 constraints. Grifols is also
advancing on the execution of its expansion plan, comprising organic and inorganic growth. As part of its organic efforts, the
company plans to open between 15 and 20 new plasma centers in 2021.
This acquisition is aligned with Grifols’
global expansion and plasma-supply diversification strategy, with 344 plasma centers worldwide: 289 in the U.S. following this
transaction and 55 in Europe across Germany, Austria and, recently Hungary. Likewise, Grifols remains committed to increasing its
supply of plasma and plasma-derived therapies to ensure patients continue to receive the treatments and healthcare they need.
In Barcelona, on 1 March 2021
|
|
Nuria Martín Barnés
|
|
Secretary to the Board of Directors
|
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
Grifols, S.A.
|
|
|
|
|
By:
|
/s/ David I. Bell
|
|
|
Name:
|
David I. Bell
|
|
|
Title:
|
Authorized Signatory
|
Date: March 1, 2021
Grifols (PK) (USOTC:GIKLY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Grifols (PK) (USOTC:GIKLY)
Historical Stock Chart
From Jul 2023 to Jul 2024